Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.43 |
| ▸ | PPARD | Q03181 | 5/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | RARB | P10826 | 2/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RARA | P10276 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10302256 | 0.98 | S1PR1 (0.43) | S1PR1S1PR3FFAR1PPARDPTPN11 | |
| SCHEMBL10302250 | 0.97 | PTPN11 (0.43) | S1PR1S1PR3FFAR1PPARDPTPN11 | |
| SCHEMBL10302251 | 0.97 | PTPN11 (0.43) | S1PR1S1PR3FFAR1PPARDPTPN11 | |
| SCHEMBL10302257 | 0.97 | PTPN11 (0.43) | S1PR1S1PR3FFAR1PPARDPTPN11 | |
| SCHEMBL10302248 | 0.92 | FFAR1 (0.46) | S1PR1S1PR3FFAR1PPARDFFAR4 | |
| SCHEMBL14766382 | 0.91 | S1PR1 (0.46) | S1PR1S1PR3FFAR1PPARDPTPN11 | |
| SCHEMBL12736567 | 0.90 | S1PR1 (0.44) | S1PR1S1PR3FFAR1PPARDPTPN11 | |
| SCHEMBL10302253 | 0.89 | MAPT (0.40) | S1PR1S1PR3FFAR1PPARDFFAR4 | |
| SCHEMBL14766083 | 0.89 | FFAR1 (0.46) | S1PR1S1PR3FFAR1PPARDPTPN11 | |
| SCHEMBL14765905 | 0.89 | S1PR1 (0.45) | S1PR1S1PR3FFAR1PPARDPTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216489-B2 | Three-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | S1PR1 1915/4885S1PR3 1056/4885FFAR1 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.